Baidu
map

青蒿素不为人知的背后--专利大战

2015-10-09 MedSci MedSci原创

北京时间10月5日下午17:30,2015年诺贝尔生理学或医学奖揭晓,来自中国科学家 Youyou Tu (屠呦呦)因发现抵御疟疾的疗法,以及两位科学家:William C. Campbell and Satoshi Ōmura因发现抵御蛔虫感染的疗法而获得此奖。科学家 Youyou Tu获得一半奖金,另外两位科学家分享另外一半奖金。研究者William C. Campbell和Satoshi Ō

北京时间10月5日下午17:30,2015年诺贝尔生理学或医学奖揭晓,来自中国科学家 Youyou Tu (屠呦呦)因发现抵御疟疾的疗法,以及两位科学家:William C. Campbell and Satoshi Ōmura因发现抵御蛔虫感染的疗法而获得此奖。科学家 Youyou Tu获得一半奖金,另外两位科学家分享另外一半奖金。

中国科学家屠呦呦则发现了Artemisinin(青蒿素),这种药物可以明显降低疟疾病人的死亡率。但成功的背后,却有着一段不为人知“一错再错”的专利问题。

专利授权的基本前提是“新”,就是在申请专利前,没有公开过(包括论文发表)

在青蒿素的研发过程中,在没有申请专利授权的情况下,研究人员在国内外就发表了一系列研究成果报告,因此也失去了国际专利权保护的机会。做科研不仅仅是埋头苦干的事情,在研发过程应该和专利申请有机的结合气力啊。专利授权后,其他方式的技术公开,都是在保护下的公开,获得专利授权的科研成果,一样可以再发表学术论文。

长期合作中的知识产权问题约定非常重要

1994年,军事医学科学院与跨国制药巨头瑞士诺华公司签署专利开发许可协议,后者负责复方蒿甲醚在国际上的研究和开发,前者则收取一定的专利使用费。这一协议,帮助复方蒿甲醚在世界多个国家获得专利,但与此同时,也宣告军事医学科学院放弃了复方蒿甲醚国际市场的销售权。

很多知识产权纠纷都是由于技术合作导致的。知识产权属于长期利益的范畴,而很多企业在合作时,对于保护长期利益的警觉性不足,其实关注知识产权条款,就是在关注长期利益。专利不是静止的,技术会衍生、可改进,这些变化都会衍生新的专利。

从最开始丧失原始专利申请权到与诺华合作丧失技术优势,青蒿素遭遇的一系列专利问题,不能说是谁的错,只能说有些遗憾。

但现在中国专利环境已经经历了30多年的锤炼,我们应该在专利申请中做的更好。

那在科研过程中,哪些是可以申请专利?

医学常见申请类型:

1,器械,装置,医用材料,试剂,
2,生物组织工程技术,如生物材料、组织构建方法
3,西药/中药/化合物的药品本身、制备方法、医药用途
4,诊断试剂,诊断试剂盒
5,经过分离并具有特定工业用途的微生物
6,物质的检测/实验方法(如:结核分枝杆菌荧光定量PCR检测方法)
7,生物技术领域,如基因、重组载体、转化体等(如:用于治疗慢性疼痛的多肽)
8,动物模型建立方法(如:小鼠烫伤模型的建立方法)
9,医用的系统(如:脑瘫患者坐姿脊柱矫正测量系统)
10,监测方法,处理方法,控制方法,评价方法

申请专利对医生而言,究竟有什么好处呢?

1、可以将自己的专利权转让而获得利益

专利的直接利益就是专利转让所得的费用,比如2004年,一位上海的中国工程院院士转让了一项新药专利,其转让费收入高达250万元。

2、专利可以为职称评定加分,为个人落户加分

随着国家及各地区对专利的逐渐重视,以第二军医大学为例,学校将专利相关指标纳入高级职称评定标准,以第一责任人获得一项发明专利授权等同发表一篇SCI文章。同时为个人落户加分。

3、获得名誉及奖励

同学术论文一样,专利也可以为研究者带来名誉,并且可以获得学校及医院的奖励。

4、和发表论文并不冲突,而且并不会因为论文的发表而影响专利权

专利授权后,其他方式的技术公开,都是在保护下的公开,获得专利授权的科研成果,一样可以再发表学术论文。

看到这里,是不是也想申请专利了呢?

专利申请是自己申请还是请代理事务所申请比较好呢?

由于专利申请文件属于法律性文件,涉及到很多具体问题,如技术方案保护范围大小的问题、专利是不是授权的客体、三性的判断等,需要大量专利法律知识和充足的经验,所以一般都是由专业的代理机构协助申请。

MedSci携手中国商标专利事务所,为广大科研工作者提供专利申请服务。

为了避免这种以上种种错误,推荐大家观看由MedSci推出的关于专利的系列课程,了解更多相关知识,也可在手机上观看:推荐下载MedSci医学APP,随时随地获取最新的科研动态。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=64204, encodeId=b4a7642046b, content=要了解。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Sat Feb 13 13:49:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62419, encodeId=72606241997, content=准备试试!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Feb 01 09:17:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38510, encodeId=c8ce38510b7, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38511, encodeId=96093851146, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38512, encodeId=82bc38512a4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38513, encodeId=e5e73851350, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38268, encodeId=de61382681c, content=很高兴medsCi出了专利申请评审相关服务,, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Sat Oct 10 09:28:00 CST 2015, time=2015-10-10, status=1, ipAttribution=)]
    2016-02-13 1de4ac4em35(暂无匿称)

    要了解。。。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=64204, encodeId=b4a7642046b, content=要了解。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Sat Feb 13 13:49:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62419, encodeId=72606241997, content=准备试试!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Feb 01 09:17:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38510, encodeId=c8ce38510b7, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38511, encodeId=96093851146, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38512, encodeId=82bc38512a4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38513, encodeId=e5e73851350, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38268, encodeId=de61382681c, content=很高兴medsCi出了专利申请评审相关服务,, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Sat Oct 10 09:28:00 CST 2015, time=2015-10-10, status=1, ipAttribution=)]
    2016-02-01 ssummer

    准备试试!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=64204, encodeId=b4a7642046b, content=要了解。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Sat Feb 13 13:49:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62419, encodeId=72606241997, content=准备试试!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Feb 01 09:17:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38510, encodeId=c8ce38510b7, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38511, encodeId=96093851146, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38512, encodeId=82bc38512a4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38513, encodeId=e5e73851350, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38268, encodeId=de61382681c, content=很高兴medsCi出了专利申请评审相关服务,, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Sat Oct 10 09:28:00 CST 2015, time=2015-10-10, status=1, ipAttribution=)]
    2015-10-12 hlycom3356

    这篇文章写的很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=64204, encodeId=b4a7642046b, content=要了解。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Sat Feb 13 13:49:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62419, encodeId=72606241997, content=准备试试!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Feb 01 09:17:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38510, encodeId=c8ce38510b7, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38511, encodeId=96093851146, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38512, encodeId=82bc38512a4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38513, encodeId=e5e73851350, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38268, encodeId=de61382681c, content=很高兴medsCi出了专利申请评审相关服务,, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Sat Oct 10 09:28:00 CST 2015, time=2015-10-10, status=1, ipAttribution=)]
    2015-10-12 hlycom3356

    这篇文章写的很好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=64204, encodeId=b4a7642046b, content=要了解。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Sat Feb 13 13:49:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62419, encodeId=72606241997, content=准备试试!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Feb 01 09:17:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38510, encodeId=c8ce38510b7, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38511, encodeId=96093851146, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38512, encodeId=82bc38512a4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38513, encodeId=e5e73851350, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38268, encodeId=de61382681c, content=很高兴medsCi出了专利申请评审相关服务,, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Sat Oct 10 09:28:00 CST 2015, time=2015-10-10, status=1, ipAttribution=)]
    2015-10-12 hlycom3356

    这篇文章写的很好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=64204, encodeId=b4a7642046b, content=要了解。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Sat Feb 13 13:49:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62419, encodeId=72606241997, content=准备试试!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Feb 01 09:17:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38510, encodeId=c8ce38510b7, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38511, encodeId=96093851146, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38512, encodeId=82bc38512a4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38513, encodeId=e5e73851350, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38268, encodeId=de61382681c, content=很高兴medsCi出了专利申请评审相关服务,, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Sat Oct 10 09:28:00 CST 2015, time=2015-10-10, status=1, ipAttribution=)]
    2015-10-12 hlycom3356

    这篇文章写的很好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=64204, encodeId=b4a7642046b, content=要了解。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Sat Feb 13 13:49:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62419, encodeId=72606241997, content=准备试试!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Feb 01 09:17:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38510, encodeId=c8ce38510b7, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38511, encodeId=96093851146, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38512, encodeId=82bc38512a4, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38513, encodeId=e5e73851350, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 13:14:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38268, encodeId=de61382681c, content=很高兴medsCi出了专利申请评审相关服务,, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Sat Oct 10 09:28:00 CST 2015, time=2015-10-10, status=1, ipAttribution=)]
    2015-10-10 vpssa

    很高兴medsCi出了专利申请评审相关服务,

    0

相关资讯

屠呦呦获奖领域——疟疾与文化和历史的纠缠

2015年诺贝尔生理学或医学奖终于在北京时间10月5日下午5:30揭晓,三位科学家因为其在抗寄生虫领域的杰出贡献,分享了今年的诺贝尔生理学或医学奖。这其中,美国科学家William C. Campbell和日本科学家Satoshi Omura因为他们开发出了抗蛔虫新药阿维菌素,为人类健康做出了重大贡献。 中国科学家屠呦呦,因为她和她的同事在青蒿素的发现、改进和发展等方面做

青蒿素的发现给我们什么启示?

青蒿素是我国创新药物研发的一个典范。从中草药知识开始找到一个挽救无数生命,被国际社会承认的主流药物是一个非常了不起的成就。主要发明者屠呦呦教授因此获得Lasker奖。诺贝尔遗嘱指出诺奖是发给为人类做出杰出贡献(而不是最有创造性、技术艰巨性等)的科学家。按照这个标准青蒿素获诺奖一点不为过。事实上如果青蒿素挽救的是几百万癌症患者的生命那屠教授可能已经得过好几次炸药奖了,但all life is not

青蒿素,为何一错再错?

2011年9月,中国女药学家屠呦呦因创制新型抗疟药——青蒿素和双氢青蒿素的贡献,获得被誉为诺贝尔奖“风向标”的拉斯克奖。可以说是中国生物医学界离诺贝尔奖最近的一次。但是,这个成功的技术背后,却是一错再错的专利故事。分析这个案例,是为了以史为鉴,在以后的工作中吸取教训,不再犯同样的错误。  丧失原始专利申请权 青蒿素的研发接近成果期的时候,我国的研究人员在国内外发表了一系列文章。197

植物源的药物:阿司匹林,青蒿素,二甲双胍......

青蒿素,砒霜是国人熟悉的源于植物和天然矿物的两种药物。实际上,我们日常使用的药物中,有很多源于植物,包括中药。象很多化疗药物,如紫杉醇,长春新碱,喜树碱等等。而经典药物中,源于植物的,甚至长盛不衰的还有很多,最牛的算是阿司匹林和二甲双胍了。 阿司匹林可能大家都知道,源于柳树皮。但是,二甲双胍,可能就很少有人知道它的来源了。实际上,最初也是源于植物。 从山羊豆说起 山羊豆(Galega o

饶毅博客:中药的科学研究丰碑

摘要1970年代早期,多数中国科学家,在文化大革命中努力生存而无机会开展研究。两位年轻的研究者屠呦呦和张亭栋,分别在发现抗疟新药青蒿素和揭示砒霜化学成分三氧化二砷对白血病的治疗作用的过程中起了关键作用。回顾四十年前开始的历程,不乏曲折和反讽。青蒿素工作源于中国帮助越南抵抗美国,三氧化二砷源于观察、验证和改进乡村中医的实践。虽然他们的药物挽救了世界上很多生命,两位研究者迄今未获国内外充分肯定,

假如青蒿素失效:消灭耐药性疟原虫成防疟重点

  柬埔寨拜林市一处名为Prey Mong kol村的儿童在经过杀虫剂处理的蚊帐中睡觉,该地区近3/4的疟疾感染者已经对以青蒿素为基础的综合疗法产生耐药性。 图片来源:PAULA BRONSTEIN 围绕湄公河三角洲的地区因为疟疾虫泛滥而声名狼藉。上世纪五六十年代,疟原虫已两次对关键药物产生耐药性,其潜在的基因突变无情地席卷全球,迫使公共卫生官员不得不寻找抵抗疟疾

Baidu
map
Baidu
map
Baidu
map